Roivant Sciences (Nasdaq: ROIV) announced that the U.S. Food and Drug Administration has approved LISRAYA (brepocitinib) 30 mg, a once-daily ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE